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Background: Decision-making in healthcare is complex. Research on coverage decision-making has focused on
comparative studies for several countries, statistical analyses for single decision-makers, the decision outcome and
appraisal criteria. Accounting for decision processes extends the complexity, as they are multidimensional and
process elements need to be regarded as latent constructs (composites) that are not observed directly. The
objective of this study was to present a practical application of partial least square path modelling (PLS-PM) to
evaluate how it offers a method for empirical analysis of decision-making in healthcare.
Methods: Empirical approaches that applied PLS-PM to decision-making in healthcare were identified through a
systematic literature search. PLS-PM was used as an estimation technique for a structural equation model that
specified hypotheses between the components of decision processes and the reasonableness of decision-making in
terms of medical, economic and other ethical criteria. The model was estimated for a sample of 55 coverage
decisions on the extension of newborn screening programmes in Europe. Results were evaluated by standard
reliability and validity measures for PLS-PM.
Results: After modification by dropping two indicators that showed poor measures in the measurement models’
quality assessment and were not meaningful for newborn screening, the structural equation model estimation
produced plausible results. The presence of three influences was supported: the links between both stakeholder
participation or transparency and the reasonableness of decision-making; and the effect of transparency on the
degree of scientific rigour of assessment. Reliable and valid measurement models were obtained to describe the
composites of ‘transparency’, ‘participation’, ‘scientific rigour’ and ‘reasonableness’.
Conclusions: The structural equation model was among the first applications of PLS-PM to coverage decision-
making. It allowed testing of hypotheses in situations where there are links between several non-observable
constructs. PLS-PM was compatible in accounting for the complexity of coverage decisions to obtain a more
realistic perspective for empirical analysis. The model specification can be used for hypothesis testing by using
larger sample sizes and for data in the full domain of health technologies.
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Across industrialized countries, many publicly funded
healthcare systems have installed mechanisms to formally
assess and appraise the coverage and reimbursement of
health technologies [1]. Since the establishment of the UK
National Institute for Health and Clinical Excellence
(NICE) and similar institutions, research on healthcare
decision-making has been extended beyond physician and
patient behaviour [2]. Generally speaking, a decision pro-
duces an action as a result of the decision process. In
healthcare, actions comprise provision of treatments, tests
or clinical strategies [3]. In relation to coverage, a
decision-making committee decides on reimbursement of
a technology. Foremost is the decision process, which
involves a variety of elements such as evidence assess-
ment, stakeholder participation or application of appraisal
criteria [4]. As such elements extend the complexity that
comprise decisions and resulting actions, suitable methods
are required for quantitative analysis.
Analogous to the regulation of environmental and
safety issues [5], the implementation of formal coverage
decision-making incurs benefits in terms of actions to-
wards efficient allocation of resources. For example, the
Swedish Pharmaceutical Benefits Board re-evaluated all
antihypertensive treatments, which resulted in savings to
the national health service of about 5% [6]. In contrast,
third-party payers who intend to regulate coverage face
costs because they need to enforce processes and con-
duct evidence assessments. From the manufacturers’ and
patients’ perspectives, decision processes also delay mar-
ket entry and the availability of treatments [7]. To
understand the functioning of decision processes, instru-
ments are needed to measure the consequences of differ-
ent specifications of decision-making.
Coverage has been analysed by description of decision
processes and qualitative and quantitative investigation of
real-world decisions. Stafinski et al. provide an inventory of
decision processes from 31 decision-makers based on avail-
able documentation [8]. Coverage decisions are subject to
influences from policy, and complex technologies may chal-
lenge pre-defined processes. Thus, hypothetical description
of decision procedures cannot capture such aspects. Vuor-
enkoski et al. identify six qualitative studies that focus on
the description of selected aspects of past decision pro-
cesses by a single committee [9]. Although qualitative
approaches provide an opportunity to describe complex
interrelationships between elements of decision-making in
detail, they do not allow measurement of the strength of
such effects mathematically. Using regression analysis, sev-
eral studies have enforced quantitative approaches to ana-
lyse real-world decision-making [10-13]. These studies
examine the relation between decision outcome and
selected appraisal criteria. Furthermore, they focus on the
UK NICE and the Australian Pharmaceutical BenefitsAdvisory Committee. A number of comparative studies
apply descriptive methods but also concentrate on selected
aspects, e.g. decision-making for cancer drugs [14-16].
To account for the complexity of decision-making, three
aspects need consideration in empirical analysis: (1) Not
all elements of decision processes can be measured by spe-
cification of variables that can be observed directly. For
example, there is discussion about the legitimacy and
transparency of decision processes being critical factors
that support the appraisal stage [17]. Such concepts can-
not be measured by observation of a single variable. So-
called latent constructs or, composites are frequently
defined from normative concepts and need operationaliza-
tion by several observable indicators. (2) The network of
linkages between elements of decision processes needs to
be accounted for because the components of decision-
making are not independent but influence each other. For
example, Erntoft argues that cost-effectiveness considera-
tions influence both assessment and appraisal [18]. (3)
Multiple interrelationships further imply accurate specifi-
cation of causal inferences. Correct description of cause
and effect offers the opportunity to conduct empirical ana-
lysis from a more realistic point of view.
Structural equation modelling comprises a group of esti-
mation algorithms that account for the complexity of
coverage decisions. Linkages between several composites
can be tested in a structural equation model (SEM) by a
combination of factor and multiple regression analysis.
Partial least square path modelling (PLS-PM) is a tech-
nique of structural equation modelling where the share of
the variance explained for one or several endogenous con-
structs specified in the SEM is maximized through a series
of ordinary least squares regressions [19]. PLS-PM is used
by a growing number of research disciplines, e.g. strategic
management or marketing [20]. However, its current ap-
plication to decision-making in healthcare and, especially,
to coverage is unclear.
The objective of this study is to present a practical ap-
plication of PLS-PM to coverage decision-making and
show how it offers a method for empirical analysis of
situations that involve multiple interrelationships among
several composites. This aim is achieved by identification
of studies that have applied PLS-PM in the context of
healthcare decision-making. The technique is then ap-
plied to a SEM that specifies a set of hypotheses on links
between the components of decision-making. It is tested
and evaluated for decisions to expand newborn screen-
ing programmes across Europe.
Methods
Identification of PLS-PM applications to decision-making
in healthcare
Four databases were searched systematically to identify
approaches that have applied PLS-PM to decision-
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tions of structural models. Studies were included if
they analysed decision-making in healthcare, at both
individual and institutional level, including coverage
and reimbursement. A detailed description of the study
identification is presented in Additional file 1: Systematic
search. The search identified two publications but none
of them dealt with coverage decision-making. Downey
and Sharp examined the adoption behaviour of worksite
health promotion by company managers using the theory
of planned behaviour [21]. Walter and Lopez examined
the acceptance of information technologies in the med-
ical sector assuming that physicians’ beliefs in their pro-
fessional autonomy may be limited through IT [22].
Also, no studies that used covariance-based SEM to ana-
lyse coverage decisions were identified.
Partial least square path modelling
Structural equation modelling includes several elements
that are different from multivariate regression analysis
[20]. A SEM consists of composites that are interrelated.
Endogenous constructs depend on one or several exogen-
ous constructs. In regression analysis, one dependent
variable is explained by several independent variables.
Specification of several endogenous constructs is not pos-
sible. In the structural model, links between several con-
structs can be defined. In the measurement models, the
relation between a composite is defined by one or several
manifest indicators that are observed directly in the data.
Depending on the causality between construct and
indicators, measurement models are either formative or
reflective. In the former, the causality goes from the indi-
cator to the construct, whereas for the latter, the direc-
tion of causality is reversed. Through application of an
iterative procedure, the PLS-PM algorithm calculates the
path coefficients between the composites and the scores
of the constructs in the structural model and the weights
and loadings of the manifest indicators in the measure-
ment models in a sequence of ordinary least square
regressions [19]. The software SmartPLS 2.0 M3 was
used for estimation of the case study using the path
weighting scheme to calculate the inner weights [23]. The
mean replacement algorithm was selected to substitute
missing values.
The case study
The applicability of PLS-PM to coverage was assessed
for a newly developed SEM which describes specific
components of decision processes and their interrela-
tionships. The motivation was to measure the effects be-
tween components that have been discussed in the
literature separately but not in combination. For specifi-
cation of the components which were regarded as com-
posites, a set of indicators that has been developed todescribe and structure the steps of coverage decision-
making was used [4,24]. For the test of applicability, a
data set of 55 coverage decisions made on newborn
screening (NBS) technologies was available. Because of
the small sample size and the expectation that decisions
on NBS incur several peculiarities within the range of
health technologies, it was not a suitable strategy to
build the measurement models by use of clustering tech-
niques [25,26]. Instead, the aim was to assess the SEM
for hypotheses testing using larger sample sizes and in
the full domain of health technologies. In the following,
the components, the hypotheses, the empirical operatio-
nalization and the data are described.
Components of coverage decision-making and their
interrelationships
A set of hypotheses was stated that rested on statements
made in the literature, empirical observations and the lo-
gical combination of the components of decision pro-
cesses. It was aimed to explore and predict the linkages
to obtain a general perspective on coverage. Empirical
studies have examined aspects that are frequently very
specific for the decision-makers under consideration
and, thus, their transferability is limited.
As no single theoretical framework exists that combines
the components of decision processes, this model rested
on two normative deliberations. To obtain reasonable and
fair decision-making, the principles of procedural justices
state that criteria have to be met such as transparency of
and stakeholder participation in decision processes are
ensured [4,17,27]. Besides, it is frequently argued that
there is not a one single criterion for making reasonable
decisions. Instead, a combination of medical, economic
and other ethical criteria is used frequently [10-12,28-32].
What is unclear is the influence of the principles of pro-
cedural justice on the reasonableness of coverage decisions
in terms of the criteria considered for appraisal.
Additionally, accounting for the use of assessment
methods to gather evidence on the considered technol-
ogy, the model specification thus consisted of four com-
ponents: ‘transparency’, ‘participation’, ‘scientific rigour (of
assessment)’ and ‘reasonableness’ [33-36]. A detailed de-
scription is provided in Table 1. As the appraisal of a
technology is the final stage before the decision outcome
is settled, it was hypothesized that the component ‘rea-
sonableness’ is influenced by the others. It was further
stated that both transparency and the degree of partici-
pation influence the rigour of assessment. An overview
of the hypotheses that describe the links between the
components is provided in Table 2.
Specification of the structural equation model
To specify the SEM, the components rested on an existing
structuring and operationalization for empirical analysis.
Table 1 Specification of constructs and measurement models for SEM of coverage decision-making
Construct Construct description Indicator Indicator description
Participation Different stakeholder groups
are involved at various
stages of decision processes
to ensure that their
interests are not
neglected [34,35,54,55].






Degree of participation reflected by
number of types of stakeholders
involved in the decision process.
High diversity of stakeholders
increases the possibility that
particular interests of single




one indicator per type of
involvement)
Number of stakeholders involved
at stages in decision process.
More involvement opportunities
result in stronger participation.
Transparency Processes are considered
transparent if relevant
information is provided
so that decisions can
be retraced [36,56].
More transparency improves
the extent to which a
decision can be controlled.
Transparency is reflected by
the degree of detail in the
documentation of processes
and decision outcomes [33,56].
Amount of information published
during or after decision process
Degree of transparency reflected
by the amount of documents
published for each decision.
Type of information provided Degree of transparency reflected
by the diversity of published
information provided – i.e. whether




Scientific rigour is defined
by the methodological standards
for generating evidence.
The assessment of effectiveness
may range from collecting expert
opinions to quantitative meta-analyses
of studies. Assessment of costs may
go from rough estimates to
comprehensive cost-effectiveness
or budget impact analyses.
Rigorous assessments are
prerequisites to reasonable
decisions that are evidence
based and accepted by
informed people [36,56].
Scientific rigour in assessment
of effectiveness
The degree of scientific rigour is
positively reflected by the
degree of methodological standards
used for the assessment of effectiveness.
Scientific rigour in assessment of
costs/cost-effectiveness
The degree of scientific rigour is
positively reflected by the
degree of methodological
standards used for the
assessment of costs/cost-effectiveness.
Reasonableness Reasonableness is defined as
the extent to which typically
accepted criteria are considered
in technology appraisal [1,18,32].
The higher their relevance
and the number of criteria considered,
the stronger the degree of
reasonableness is reflected.
Relevance of criteria that
contribute to reasonable
appraisal (i.e. clinical (effectiveness:
health benefit; effectiveness:
other benefit (e.g. knowledge
of diagnostic test result)),
economic (cost-effectiveness,
budget impact) and other
ethical criteria (severity of
the disease, equitable
access to care), one indicator
per criterion)
The higher the relevance of clinical,
economic or other ethical criteria,
the higher the degree of
reasonableness of the decision.
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process and appraisal criteria [4]. It describes the stylized
steps of a decision process from the point where a tech-
nology enters a healthcare market to its diffusion into
routine use. The following steps were considered: stake-
holder ‘participation’; ‘publication’, which reflects infor-
mation about the transparency of decision processes;
‘scientific rigour of assessment’ by methods such as sys-
tematic literature review or cost-effectiveness analysis;and ‘appraisal’ in terms of decision-making criteria which
determine whether the technology should be funded given
the available evidence on effectiveness and costs and add-
itional ethical considerations. This step reflects the reason-
ableness of decision-making. Each step in the framework
corresponds with a set of indicators for empirical opera-
tionalization which has been proposed in the literature
[24]. This collection of variables has been validated by a
small number of decisions and expert discussions.
Table 2 Specification of hypotheses: links between components of coverage decision processes
Component: cause Component: effect Hypothesized relationship
Transparency ! Reasonableness The more documents are provided that strongly relate to
dissemination of the process and decision outcome, the
higher is the extent to which the decision is appraised
against reasonable criteria because this facilitates a better
control of the decision-makers.
Participation ! Reasonableness The more stakeholders participate in different stages of
decision-making, the more they mutually ensure that
the technology is appraised against reasonable criteria.
Scientific rigour
of assessment
! Reasonableness The higher the methodological standards by which the
technology is assessed, the higher is the extent to which
the decision is appraised against reasonable criteria,
because decision-makers can draw upon better evidence
regarding whether the criteria are met.
Transparency ! Scientific rigour of
assessment
The more documents are provided that strongly relate
to dissemination of the process and decision outcome,
the higher the methodological standard of technology
assessment because the methodological quality can be
better controlled by the scientific community.
Participation ! Scientific rigour of
assessment
The more stakeholders participate in different stages of
decision-making, the higher the scientific standard of
technology assessment because more evidence
is identified and improvements of a weak evidence basis
can more easily
be enforced.
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decision-making were considered as composites that de-
fine the components, whereas the set of indicators pro-
vided the definition of the measurement models
(Figure 1). A description of constructs and correspond-
ing measurement models which were defined in the re-




Number of participating 
stakeholders 
Scientific rigour in 
assessment of effectiveness 
Scientific rigour in 
assessment of costs/cost-
effectiveness 
Number of stakeholders 
participating through 
information provision 
Number of stakeholders 
participating in appeal 
Number of stakeholders 











Figure 1 SEM for coverage decision-making.Data
Data was obtained from an internet survey of decisions
for expansion of NBS programmes in the European
Union. NBS includes a number of promising technolo-
gies relevant to third-party payers. Of these, tandem
mass spectrometry allows screening of multiple disor-
ders in one step. Experts provided information aboutTrans-
parency 
Amount of information 





Type of information provided 
Effectiveness, health gain 
Effectiveness other benefit 
Budget impact 
Cost-effectiveness 
Severity of the disease 
















Number of stakeholders involved in decision process 2.84 1.23
Number of stakeholders participating through information provision 1.31 1.10
Number of stakeholders participating in appeal 0.31 0.60
Number of stakeholders participating in voting 1.13 0.98
Construct: Transparency
n %
Type of information provided 0 - No information available 5 9.09
1 - Only process-related information available 3 5.45
2 - Only outcome-related information available 30 54.55
3 - Outcome- and process related information available 17 30.91
4 - Full documentation 0 0.00
Mean St.d.
Amount of information published during or after decision process 2.05 1.39
Construct: Scientific rigour of assessment
n %
Scientific rigour in assessment of effectiveness 0 - No assessment of effectiveness/other 1 1.82
1 - At least based on expert opinion 10 18.18
2 - At least systematic literature review 36 65.45
3 - At least quantitative meta-analysis of studies 8 14.55
Scientific rigour in assessment of costs/cost-effectiveness Missing 4 7.27
0 - No assessment of costs/CE 2 3.64
1 - Cost estimate 39 70.91
2 - Cost-effectiveness analyses 10 18.18
Construct: Reasonableness
Aspects considered for appraisal n %
Effectiveness, health gain 0 - Not relevant 6 10.91
1 - Relevant 14 25.45
2 - Strongly relevant 35 63.64
Effectiveness, other benefit 0 - Not relevant 38 69.09
1 - Relevant 14 25.45
2 - Strongly relevant 3 5.45
Budget impact 0 - Not relevant 38 69.09
1 - Relevant 15 27.27
2 - Strongly relevant 2 3.64
Cost-effectiveness 0 - Not relevant 36 65.45
1 - Relevant 12 21.82
2 - Strongly relevant 7 12.73
Effect on equitable access to healthcare 0 - Not relevant 32 58.18
1 - Relevant 22 40.00
2 - Strongly relevant 1 1.82
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Table 3 Frequencies of indicators for case study on NBS in Europe (Continued)
Severity of the disease 0 - Not relevant 12 21.82
1 - Relevant 15 27.27
2 - Strongly relevant 28 50.91
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for medium-chain acyl-CoA dehydrogenase deficiency,
cystic fibrosis, congenital adrenal hyperplasia or other
conditions. Forty-three respondents completed the
questionnaire and the response rate was 70%. In the
questionnaire, at least one question was stated for each
construct (see Additional file 2: Survey questionnaire).
A detailed description of the survey has been provided
elsewhere [37].
From 21 countries, a total of 55 decisions were
obtained. All variables to estimate the SEM arose from
the data set and were specified as ordinal or count vari-
ables according to the definitions provided in Table 2.
An overview of descriptive statistics including the fre-
quencies of categories for each indicator is provided in
Table 3. Data preparation was performed with SAS Ver-
sion 9.2 [38].Evaluation of the structural equation model
For PLS-PM, no global goodness-of-fit criterion exists be-
cause it is assumed that the variance is distribution free.
Alternatively, a set of standard measures for PLS-PM
exists according to which reliability and validity of the
model estimation were evaluated [19,20,39]. Although all
results were obtained from the iterative estimation at one
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Figure 2 SEM, estimation results after first estimation1.before the structural model was assessed by another set of
measures. Reliable and valid measurement models are pre-
requisites for the evaluation of the structural model. All
measures were obtained from the reports provided in
SmartPLS [23]. As the SEM does not contain formative
measurement models, these measures were neglected.Evaluation of reflective measurement models
The reliability of the reflective − i.e. the causality goes
from the construct to the indicators − measurement
models was assessed at construct and indicator level. At
construct level, composite reliability was considered, that
measures whether the indicators consistently represent
the same construct and the systematic error is consid-
ered to be zero. Composite reliability accounts for the
indicators’ weights and is considered acceptable above a
value of 0.7 for established constructs and above 0.6 in
the early stages of research [19]. At indicator level, the
factor loadings reflect the indicator’s variance explained
by the construct. To assume reliable measures, at least
50% of the variance should be explained, which is
reflected by loadings greater than 0:7  ﬃﬃﬃﬃﬃﬃ0:5p .
Validity was evaluated through convergent and dis-
criminant validity. Convergent validity assumes that the
set of indicators uniquely represents the underlying con-
struct. For this purpose, the average variance extractedTrans-
parency
Amount of information 
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indicators of the reflective construct relative to the total
amount of variance, including the variance of the meas-
urement error. To evaluate discriminant validity, two
criteria were used that appraise whether the reflective
constructs are sufficiently distinct from each other. First,
the Fornell–Larcker criterion compares the AVE of a
composite with the squared correlations between the
construct and any other construct of the model. Dis-
criminant validity can be stated if the AVE of the com-
posite is larger than any other squared correlation.
Second, the cross-loadings were compared to see
whether the loadings with the corresponding construct
were the highest.
Evaluation of the structural model
At the level of the structural model, the path coefficients
were evaluated first in terms of sign and significance.
They reflect the standardized beta coefficients for which
asymptotic t-statistics were computed from the boot-
strapping procedure. Second, the determination coeffi-
cient R2 – analogous to multiple regression – reflects
the level or share of the composites’ explained variance.
It was analysed for the endogenous composites. Third,
the effect size f2 was computed to determine whether an
exogenous construct substantially influenced an en-
dogenous construct. Similar to the traditional partial F-
test, the change in R2 is computed if the respective ex-
ogenous construct is omitted. Fourth, the predictive
relevance of the structural model was evaluated to deter-
mine how well the model parameters can be recon-
structed using the model and the PLS parameters. For
this purpose, the blindfolding procedure was performed
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Figure 3 Selected, estimation results for newborn screening program
*: p-value < 0.1.(omission distance: 7). It displays the relative predictive
impact of a construct. Values above zero indicate the
presence of predictive relevance [40].Model selection
As the SEM is at an early stage of development, it was
assessed whether improvements in respect of model reli-
ability and validity can be achieved. The model selection
was based on the evaluation measures of the measure-
ment models. It was suspected that, compared with
other technologies, the case study of NBS inherits some
peculiarities. Cost-effectiveness as decision criterion may
have not been as relevant as for pharmaceuticals [41].
Besides, considered conditions are typically severe herit-
able diseases which increase mortality and morbidity
from infant age [42]. A modified SEM was then esti-
mated and evaluated. Besides obtaining first estimations
of the hypotheses for the case study of NBS, it was
aimed to discuss implications for a general application
of the SEM and PLS-PM as modelling technique for
coverage decision-making.Results
Results for reflective measurement models
In the first estimation, the evaluation measures of re-
flective measurement models displayed some weak-
nesses. Figure 2 displays the estimation results. A
detailed overview of all evaluation measures is provided
in Additional file 3: Evaluation measures. Reliability at
construct level assesses whether the indicators consist-
ently represent the same construct and the relevance of
systematic errors. Accounting for the stage of develop-
ment of the SEM, this was fulfilled for all constructs.Trans-
parency 
Amount of information 
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mes in Europe. legend: ***: p-value < 0.01; **: p-value < 0.05;
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acceptable at early stages of research [19].
Regarding indicator reliability, the factor loading,
which represents the variance explained by the con-
struct, was below 0.7 in five of six indicators of the ‘rea-
sonableness’ construct. This indicates a lack of reliability
as the shared variance between the construct and the
indicators is then lower than the variance of the meas-
urement error. Below a value of 0.4, indicators should be
eliminated [43]. The indicators ‘number of stakeholders
participating in appeal’ of the ‘participation’ construct
and the ‘relevance of effectiveness in terms of other ben-
efits in the ‘reasonableness’ construct were the indicators
with values clearly below 0.4.
Regarding validity, the evaluation measures for conver-
gent and discriminant validity also indicated a need for
model modification. The average variance extracted
(AVE), which describes whether the set of indicators
uniquely represents the underlying construct, was less
than 0.5 for the constructs ‘participation’ and ‘reason-
ableness’. This indicates that more than half the variance
extracted results from the variance of the measurement
error. Concerning discriminant validity to assess whether
the constructs are sufficiently distinct from each other,
the evaluation measures disclosed weaknesses in the
‘participation’ and ‘reasonableness’ constructs. The
Fornell−Larcker criterion, which compares the AVE of a
composite with the squared correlations between the
construct and any other construct, revealed that at least
one squared correlation with another construct was
higher than the AVE for the construct ‘reasonableness’.
A comparison of the loadings with the indicators’ cross-
loadings with other constructs showed that values were
at a maximum for all indicators except ‘number of stake-
holders participating in appeal’ of the ‘participation’
construct.
According to identified weaknesses, two indicators
were removed because of their lack of reliability. Con-
cerning the construct ‘reasonableness’, the indicator that
reflects the relevance of effectiveness in terms of other
benefits was removed. The same applied for the indica-
tor ‘number of stakeholders participating in appeal’ of
the ‘participation’ construct.
After re-estimation, criteria for reliability were fulfilled
at the construct and indicator level for the reflective
measurement models. The selected SEM is depicted in
Figure 3, which includes the estimation results. Regard-
ing reliability at indicator level, all factor loadings were
higher than 0.4 except for the indicators ‘number of sta-
keholders involved in voting’ (loading 0.318) and ‘scien-
tific rigour in assessment of effectiveness’ (loading
0.344). Convergent validity was fulfilled for all constructs
except the construct ‘reasonableness’. Here, the AVE has
increased to a value of 0.342 but was still below 0.5.Discriminant validity could be stated without caveat for
all constructs. Both the Fornell−Larcker criterion was
fulfilled and indicator loadings were at maximum at the
assigned constructs. Bearing the weaknesses of indicator
reliability and convergent validity in mind, the measure-
ment models were considered acceptable for evaluation
of the structural model.
Results for the structural model
The structural model was not rejected. The measures for
R2 revealed that, for the construct ‘reasonableness’, 56%
of the share of the variance and, for the construct ‘scien-
tific rigour’, 7% of the share of the variance was
explained in the model. Three of the five hypotheses
were supported for decision-making on NBS technolo-
gies. Their path coefficients, which are interpreted as
standardized beta coefficients, had the hypothesized dir-
ection and were significant at least at the 90%- level. A
higher degree of stakeholder participation (path coeffi-
cient 0.486; p < 0.001) and transparency (0.208;
p = 0.098) increased the degree of making reasonable
coverage decisions. Furthermore, the degree of transpar-
ency positively influenced the degree of scientific rigour
(0.287; p = 0.051). The link between the constructs ‘sci-
entific rigour’ and ‘reasonableness’ had the intended sign
but was not significant (p = 0.57). It also had a very small
path coefficient. A link between participation and ‘scien-
tific rigour’ was not supported, as the path was negative
and not significant (p = 0.58). Thus, the degree of partici-
pation did not influence the rigour of assessment.
The values of the effect size f2 which reflect the influ-
ence of the exogenous on the endogenous constructs in
terms of the share of the variance, showed that the con-
structs ‘participation’ and transparency’ contributed to
explanation of the endogenous constructs to varying
degrees. For the construct ‘participation, no effect was
found for the contribution to the construct ‘scientific
rigour’ while a medium effect was identified for the con-
tribution to the construct ‘reasonableness’. The con-
struct ‘transparency’ both contributed to explanation of
the endogenous constructs with a weak effect. The
Stone−Geisser test, which assesses the model’s capability
to predict, revealed mixed results. No predictive rele-
vance was identified for the construct ‘scientific rigour’
(q2=−0.01) while a small predictive relevance was found
for the reasonableness construct (q2= 0.04).
Discussion
The applicability of PLS-PM to coverage needs critical
reflection as comparison with existing studies is not pos-
sible. The stated constructs can be used for further in-
vestigation of linkages between the components of
coverage decision-making. The measurement models
could be operationalized in a reliable and valid manner.
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tors and constructs could be validated at measurement
model level, further exploration is needed at the level of
the structural model, especially if the tested hypotheses
hold for other technologies. In spite of this, the qualita-
tive interpretations of the results provide insight into
whether PLS-PM produces plausible estimates and
whether it is a suitable application for hypothesis testing
using large data sets.
The case study reveals that the influence from the de-
gree of stakeholder participation on reasonableness is
about twice as influential as the degree of transparency
in European NBS decisions. Besides, the degree of trans-
parency significantly influences the level of methodo-
logical standards for evidence assessments. Thus, the
estimation results are capable of demonstrating that the
process components of coverage decisions that describe
elements of procedural justice and definition of substan-
tive appraisal criteria influence each other. No influence
was found for the path between participation and scien-
tific rigour which suggests that NBS technologies were
assessed independently from the influence of stake-
holders. Also, the R2 for the construct ‘scientific rigour’
was small which suggests that it is not well explained by
the exogenous constructs of the SEM. On the contrary,
considering the multiplicity of influences on coverage
decision-making, the value of R2 of the ‘reasonableness’
construct can be considered acceptable. Examples are in-
stitutional configurations such as the level of decision-
making or the implementation of the technology within
the reimbursement scheme which are not described in
this model [44].
Some features of NBS in comparison with other health
technologies need to be kept in mind when interpreting
the results. Although evaluation measures for the con-
struct ‘scientific rigour’ are acceptable, the path coeffi-
cient had no significant influence on the degree of
‘reasonableness’. This finding is supported in the litera-
ture on evaluation of NBS technologies, which states
that cost-effectiveness information have frequently not
been considered for appraisal [41]. This is also in line
with the small correlation between the indicator that
reflects the scientific rigour of assessing costs/cost-ef-
fectiveness and the construct. Compared with technolo-
gies such as pharmaceuticals, coverage may not have
been regulated as strictly, which is indicated by a low
uptake of health technology assessment [37]. Further-
more, survey respondents stated that funding of the
screening tests was frequently negotiated between the
payer and service providers, for which processes have
not been defined (yet) or did not require disclosure of
information. Thus, the degree of stakeholder participa-
tion had the strongest influence of the reasonableness of
decision-making and was significant. Regarding theconstruct ‘reasonableness’, the effectiveness in terms of
the health gain from testing and the severity of the dis-
ease were the indicators that reliably reflected the con-
struct in the selected model estimation. A reason why
cost-related aspects were not as meaningful may be the
relatively low cost of the screening technologies and, for
selected disorders, the high perceived effects from
screening of newborns [42]. Decisions on NBS were
often made by institutions that do not typically decide
on coverage of health technologies. Especially for phar-
maceuticals, criteria such as cost-effectiveness and
budget impact are perceived as being more relevant
[1,13]. Thus, for the construct ‘reasonableness’, all cri-
teria should be used at the start of the analysis if
decision-making on health technologies is examined.
Also, principal component or factor analysis on all
observed indicators could be applied if the sample size is
sufficient.
PLS-PM manages to account for the complexity be-
tween the components stated in the model. As the goal
of PLS-PM is to support the exploration and prediction
of models under development, it provides guidance as to
which link suggested for coverage decisions can be iden-
tified empirically. Before the other hypotheses are ultim-
ately rejected, further evaluation is needed about
whether this is also true for other technological areas.
The relation between scientific rigour and reasonable-
ness might be significant as these components are tied
more closely in other processes, e.g. the technology ap-
praisal by the UK NICE [45]. Similarly, the relation be-
tween the degree of participation and scientific rigour
might be meaningful in other technological domains. In
many countries, pharmaceutical manufacturers need to
submit evidence on their products to obtain coverage
[46]. Typically, this was not the case for NBS technolo-
gies. Finally, the model demonstrated that PLS-PM may
be applicable for contexts of decision-making where
‘soft’ influences with high complexity and multiple links
matter. Besides decision-analytic modelling, such
approaches are demanded in healthcare, e.g. shared deci-
sions between patients and physicians [47]. Nevertheless,
a correct specification of the theoretical model is a cru-
cial requirement to accurately interpret the empirical
results. The conceptual specification of this SEM needs
further elaboration through expert validation and discus-
sion of the theoretical foundations. Furthermore, making
confirmatory statements is limited when using PLS-PM.
Instead, covariance-based SEM should be used [20].
The test of applicability of PLS-PM has some limita-
tions. The estimation was based on a small sample and
on decisions made for a very specific technological area.
However, the sample size was sufficient according to
established rules of thumb for PLS-PM [20]. The PLS-
PM results were not compared with other modelling
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ate regression analysis. However, application of these
techniques is limited for the reasons for which PLS-PM
was considered suitable, namely the capability to ac-
count for small sample sizes and no possibility of defin-
ing formative measurement models. Omitting possible
influences of the survey sample, it was not possible to
split the data for the different stages of model develop-
ment (i.e. model specification, test of significance) be-
cause of the small sample size. A split sample design is
appropriate for this purpose but was not applied.
Regarding model specification, theory dependency
of the results cannot be neglected because the causal
dependencies were specified without testing for other
possible structures for the network of considered com-
ponents. Bayesian network analysis would be suited to
train and validate the model structure [48,49]. However,
required data was missing for this purpose. No expert
opinion about the possible causal relationships and no
information about the probabilistic relationships be-
tween constructs and indicators were available. By col-
lection of further information, e.g. through an expert
workshop, the model estimation could be used in future
studies for validation. However, while theoretical con-
siderations are developing, this study provides a first
exploratory estimation of a SEM for coverage decision-
making as well as measurement models that can be
used for further analysis.
Potential unobserved heterogeneity between decisions
has not been accounted for. Decision practices may dif-
fer by healthcare system or technological characteristics.
However, no distinct explanatory variables have been
suggested for coverage decision-making in the literature.
To treat heterogeneity, methods for PLS-PM are avail-
able to identify plausible clusters ex post. Such techni-
ques have been proved appropriate in marketing
research [50], and similar approaches have been used in
other contexts of health economics [51].
This study has quantitatively assessed the procedural
aspects of decision-making such as stakeholder partici-
pation and transparency, which have been claimed as
relevant for fair and legitimate decision-making [17].
The accountability for reasonableness framework has
predominantly been evaluated by qualitative approaches
for which the evaluation of the effects frequently
remains subject to judgements from a few case studies
[52]. Furthermore, the framework neglects appraisal cri-
teria and consensus on adequate assessment methods
[53]. Specification of composites and several endogenous
variables allows the combining of both process and ap-
praisal simultaneously.
Compared with existing empirical research, the appli-
cation of PLS-PM demonstrates that dependencies be-
tween several constructs can be tested when using smallsample sizes. Previous work focuses on dependencies be-
tween the decision outcome and selected appraisal cri-
teria [10-13]. Relating to the work of Vuorenkoski et al.,
the estimation results have reconfirmed the relevance of
transparency and stakeholder participation to ensure the
quality of decision-making in the case of NBS [9].Conclusions
This study presents a practical application of PLS-PM to a
set of hypotheses for coverage decision-making on new-
born screening programmes. Although PLS-PM is estab-
lished in areas such as marketing and a comprehensive set
of evaluation measures is available to assess model reliabil-
ity and validity, the SEM on coverage in this study is
among its early applications in healthcare. Accounting for
the early stage in research, the estimates produce meas-
urement models for the constructs ‘transparency’, ‘partici-
pation’, ‘scientific rigour’ and ‘reasonableness’, which can be
used for further model validation and hypothesis testing.
The structural model results support the presence of three
influences for decisions on newborn screening in Europe:
(1) the influence of stakeholder participation and (2) trans-
parency on the degree of making reasonable coverage
decisions; and (3) the effect of transparency on the degree
of scientific rigour of assessment.
PLS-PM allows the testing of hypotheses in situations
where there are multidimensional interrelationships and
composites that need operationalization by several ob-
servable indicators. This estimation technique is thus
compatible in accounting for the complexity of coverage
decision-making to obtain a more realistic perspective of
the influences between components of decision pro-
cesses and appraisal criteria.Additional files
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